Whole genome sequencing in an acrodermatitis enteropathica family from the Middle East. by Abu-Duhier, F. et al.
Research Article
Whole Genome Sequencing in an Acrodermatitis Enteropathica
Family from the Middle East
Faisel Abu-Duhier,1 Vivetha Pooranachandran,2 Andrew J. G. McDonagh,3
Andrew G. Messenger,4 Johnathan Cooper-Knock,2 Youssef Bakri,5 Paul R. Heath ,2
and Rachid Tazi-Ahnini 4,6
1Prince Fahd Bin Sultan Research Chair, Department of Medical Lab Technology, Faculty of Applied Medical Science,
Prince Fahd Research Chair, University of Tabuk, Tabuk, Saudi Arabia
2Department of Neuroscience, SITraN, The Medical School, University of Sheffield, Sheffield S10 2RX, UK
3Department of Dermatology, Royal Hallamshire Hospital, Sheffield S10 2JF, UK
4Department of Infection, Immunity and Cardiovascular Disease, The Medical School, University of Sheffield, Sheffield S10 2RX, UK
5Biology Department, Faculty of Science, University Mohammed V Rabat, Rabat, Morocco
6Laboratory of Medical Biotechnology (MedBiotech), Rabat Medical School and Pharmacy, University Mohammed V Rabat,
Rabat, Morocco
Correspondence should be addressed to Rachid Tazi-Ahnini; r.taziahnini@sheffield.ac.uk
Received 4 April 2018; Revised 28 June 2018; Accepted 26 July 2018; Published 7 August 2018
Academic Editor: Gavin P. Robertson
Copyright © 2018 Faisel Abu-Duhier et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
We report a family from Tabuk, Saudi Arabia, previously screened for Acrodermatitis Enteropathica (AE), in which two siblings
presented with typical features of acral dermatitis and a pustular eruption but differing severity. Affected members of our family
carry a rare genetic variant, p.Gly512Trp in the SLC39A4 gene which encodes a zinc transporter; disease is thought to result
from zinc deficiency. Similar mutations have been reported previously; however, the variable severity within cases carrying the
p.Gly512Trp variant and in AE overall led us to hypothesise that additional genetic modifiers may be contributing to the disease
phenotype.Therefore whole genome sequencing was carried out in five family members, for whommaterial was available to search
for additional modifiers of AE; this included one individual with clinically diagnosed AE. We confirmed that the p.Gly512Trp
change in SLC39A4 was the only candidate homozygous change which was sufficiently rare (ExAC allele frequency 1.178e-05) and
predicted deleterious (CADD score 35) to be attributable as a fully penetrant cause of AE. To identify other genes which may carry
relevant genetic variation, we reviewed the relevant literature and databases including Gene Ontology Consortium, GeneMANIA,
GeneCards, and MalaCards to identify zinc transporter genes and possible interacting partners. The affected individual carried
variants in RECQL4 and GPAA1 genes with ExAC allele frequency <0.01 and CADD score >10. p.Gly512Trp is highly likely to be
the pathogenic variant in this family. This variant was previously detected in a Tunisian proband with perfect genotype-phenotype
segregation suggestive of pathogenicity. Further research is required in this area due to small sample size, but attention should be
given to RECQL4 and GPAA1 to understand their role in the skin disease.
1. Introduction
Acrodermatitis Enteropathica (AE) is a rare inherited
metabolic condition that affects zinc absorption and inher-
itance is often seen in an autosomal recessive pattern [1].
The frequency of inherited cases is estimated at 1:500,000
individuals with no obvious correlation in race or gender
[2]. The manifestations of AE include alopecia, diarrhoea,
dermatitis, growth retardation, and behavioural changes.
Although AE has been attributed to fully penetrant homozy-
gous mutations in the SLC39A4 gene, severity is variable
even within individual families [3] suggesting that additional
genetic modifiers may play a role.
Measurement of plasma zinc is the commonestmethod of
identifying patients with AE, and reduced levels <60 ug/dL
were noted in patients B03 and B06 in the original study
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Figure 1: Pedigree analysis to demonstrate the family of AE and the sequenced individuals for this study. Genome sequence of the following
samples: A01, A02, B03, AB01, and AB02. Only B03 and B06 are affected (one male sibling was also affected, but he died). Note. Shading in
blue displays the individuals affected by the disease.
which were correlated with their typical AE symptoms.
However, limitations of zinc testing have been highlighted
by Garza-Rodriguez et al. (2015) [4] who reported a rare
case of AE presenting with two novel missense mutations
of the SLC39A4 gene associated with periorificial and acral
dermatitis only and with normal plasma levels of zinc.
The family in this study was previously screened and
analysed by Abu-Duhier et al. 2017 [3] to identify the
pathogenic mutation. In this analysis DNA samples obtained
from eleven individuals were amplified by polymerase chain
reaction and Sanger sequenced. This comprised both parents
and all the siblings including the affected individuals with
their respective partners. A homozygous alternate allele in
chromosome 8 at position 145638714 was identified in the
gene SLC39A4 (solute carrier 39 member 4) which is a
zinc transporter. This mutation was present only in the
two affected members B03 and B06 presenting with the AE
phenotype (Figure 1). The mutation gave rise to a change
from the neutral aliphatic amino acid glycine to the highly
hydrophobic aromatic tryptophan, with genotype c.1534G>T
at position p.Gly512Trp. Although there was strong evidence
that this mutation is the cause of AE in this family, sever-
ity was variable suggesting that other modifiers may be
present. Moreover, because sequencing was limited to a small
number of genes, it is possible that alternative homozygous
pathogenic change in a zinc transporter gene may have been
missed. Others have reported the p.Gly512Trp change in a
patient with AE [1], but the role of genetic modifiers has not
previously been examined.
To exhaustively define the genetic basis of AE in our
patients, the whole genome of available family members has
now been evaluated. In this study, we aimed to identify
pathogenic and relevant modifier genes associated with
familial AE. On this occasion the proband B03, his parents
A01 andA02, and unaffected familymembersAB01 andAB02
were examined by whole genome sequencing. Two additional
family members were utilised as population controls in order
to eliminate shared, but nonrelevant alleles.
2. Materials and Methods
Ethical approval was obtained from both University of Tabuk
and University of Sheffield, and written informed consent
was obtained to use genetic data for research purposes.
Blood samples were available from 5 members of the fam-
ily with hereditary AE and were initially sequenced (as
discussed above), followed by whole genome sequencing.
The individuals studied were the affected child B03, his
parents A01 and A02, and two unrelated family members
AB01 and AB02 who were included as individuals from the
same population background (Figure 1). Both lanes of three
HiSeq 2500 Rapid Run were used to multiplex and sequence
the five samples. To produce fastq files, bcl2fastq version
1.8.4 was used with adapter trimming further modified to
accept a single mismatch in the index sequence. BWA ALN
version 0.7.5a was used to map reads by lane to the human
reference genome hg19. Picard version 1.101 was used to
mark duplicate reads followed by realignment around InDels
using GATK version 2.6-5-gba531bd. Picard was then used
to merge lane-level bam files, with additional marking of
duplicates and realignment around InDels on the complete
bam file. GATK HaplotypeCaller was used to call variants.
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Table 1: “R” software was used to identify the deleterious zinc transporter gene in B03. An EXAC frequency of <0.01 and CADD score of >10
were accepted. Excluding synonymous variants, at position Chr8:145638714 of the SLC39A4 gene, c.G1534T and p.G512W, portrayed as a rare
mutation in comparison to other identified genes and genetic variants. Note. Please see Sup Materials 2 for complete list of zinc transporter
genes derived by “R” software for B03.
Gene Chromosome Start-End Exon Nucleotide substitution Protein substitution EXAC Frequency CADD Score
SLC39A4 Chr8 145638714 10 c.G1534T p.G512W 1.178e-05 35
The minimal calling quality was accepted at 1, allowing 10
alternative haplotypes. GATK was further used to calculate
coverage statistics.
Variant calling files of the five individuals were automat-
ically annotated using wANNOVAR to provide information
including genomic annotation, frequency of variant observed
in controls, and CADD scores. “R” software was used to anal-
yse the annotated variants. Relevant literature was reviewed
and GO consortium data used to identify all zinc transporter
genes including SLC39A4. Variants in exonic regions of zinc
transport genes were filtered by ExAC frequency and CADD
score using “R” to identify rare, predicted deleterious variants
present in a homozygous form (see sup materials). An ExAC
frequency <0.01 and CADD score >10 were employed to
suggest a deleterious variant. (ExAC allele frequency suggests
the relative frequency of an allele at a genetic locus in
a population [5]; CADD score helps measure the level of
toxicity of a genetic variant such that a value of 10 defines the
variant to be within 10% of a damaging variant in the human
genome.) The analysis was repeated in the other sequenced
individuals to determine whether the toxic mutation was
present in relatives.
To extend the analysis beyond zinc transporter genes,
GeneMANIA was used to identify genetic interactions of
SLC39A4. Interacting partners were screened for poten-
tial rare deleterious variants although the requirement for
homozygosity was relaxed to include heterozygous variants.
3. Results
3.1. Only the Homozygous p.Gly512Trp SLC39A4 Variant Is
Sufficiently Rare and Deleterious to Cause AE in Our Pedigree.
The identified deleterious SLC39A4 variant p.Gly512Trp
(with ExAC frequency of 1.178e-05 and CADD score of 35)
was present in homozygous form in B03 (Table 1). As would
be expected the same p.Gly512Trp change was found to be
present in an heterozygous form in both parents, A01 and
A02, but was not found in the unaffected relatives. The
remainder of identified variants in SLC39A4 and all other
screened zinc transport genes demonstrated either a low
CADD score or a high ExAC frequency implying a benign
or uncertain significance (Sup Materials 2).
3.2. Screening SLC39A4 Interacting Partners Identified Rare
Deleterious Variants in Candidate Modifier Genes. The
patient B03 suffered a particularly severe form of AE
and therefore is a good candidate to identify additional
deleterious genetic modifiers of AE. To identify candidate
genes which are known to interact with SLC39A4, we used
GeneMANIA (https://genemania.org) to identify relevant
protein-protein interactions, coexpressed genes, and genes
of related function based on transcription and phenotypic
screening profiles. The interaction databases used by Gen-
eMANIA included BioGRID and Pathway Commons, both
including primary research studies. Databases GeneCards
and MalaCards were then used to obtain information on the
identified genes (SupMaterials 3).The interacting genes were
screened for rare deleterious variants which may have nega-
tively impacted upon the function of SLC39A4 and thus the
AE phenotype in our patient. With specific focus on exonic
regions of the genes and nonsynonymous mutations, “R”
analysis demonstrated two genes that were within acceptable
ExAC allele frequency and CADD score range (<0.01, >10):
GPAA1 and RECQL4, suggestive of significant interaction
with SLC39A4 in developing the disease phenotype in B03.
4. Discussion
AE appears to occur mainly in France and Tunisia. The
p.Gly512Trp variant was previously identified in a Tunisian
family [1]. All published mutations in the human SLC39A4
gene have been collated (Table 2). In the majority of cases,
pathogenic variants were present in a homozygous or com-
pound heterozygous state in AE. Families identified across
a number of countries with AE have been shown to carry
over 30 different mutations in SLC39A4, including deletions,
nonsense, missense, and splice-site alterations [6]. Schmitt
et al. [1] reported mutations including p.Gly512Trp and
p.549delLeu affecting amino acids that were highly conserved
between a number of species. Variants p.Gly512Trp and
p.549delLeu were detected in homozygous state in Tunisian
and Swedish probands, respectively, and the toxic mutation
was not identified in any of 164 control chromosomes from
North Africa included in their study. Moreover, there was
perfect segregation between the genotype and phenotype
in the pedigree suggesting a high likelihood for AE to be
associated with SLC39A4 gene. As previously described by
Abu-Duhier et al. [3], the mutation was located in a putative
transmembrane domain and likely to alter zinc absorption
by reducing transcription/ translation of SLC39A4.Heterozy-
gous individuals tend to be asymptomatic carriers rather than
manifesting the disease phenotype [7]. A significant feature of
AE overall and our family in particular is variable phenotype
even between individuals with the same genetic change in
SLC39A4 [3]. It is anticipated the AE phenotype could be
dependent on either modifier genes or an unknown putative
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Table 4: GPAA1 and RECQL4 genes both demonstrated a likelihood of being modifier genes of SLC39A4 in developing AE in B03. Note.
Please see Sup Materials 3 for “R” software version of complete list of interacting partners with SLC39A4 gene for B03.
Gene Chromosome Start-End Exon Nucleotide substitution Protein substitution EXAC Frequency CADD Score
GPAA1 Chr8 145140564 11 c.G1540A p.A514T 0.0053 15.04
RECQL4 Chr8 145740364 9 c.C1576T p.L526F 0.0007 16.37
AE gene. Hence we have screened for additional genetic
modifiers of SLC39A4 function within an individual with a
particularly severe AE phenotype [3].
Our data suggests that the p.Gly512Trp change is the
likely cause of disease in our family because it is the only
homozygous, rare, and predicted deleterious change within
a zinc transporter gene which is present within the affected
patient and absent (or heterozygous) in unaffected family
members. In addition we identified two rare and predicted
deleterious genetic variants in SLC39A4 interacting partners
which may have a role in the development of the particularly
severe AE phenotype in our patient: RECQL4 and GPAA1
(Table 4). Interestingly Nistor et al. [8] reported that the
complete clinical triad of features inAEwas only documented
in 20% of patients, questioning if only one gene is responsible
and ifmodifier genes could be involved in the variable clinical
characteristics. Patients with mutation in the RECQL4 gene
have several characteristic features similar toAE; for example,
Bernstein et al. [9] reported a RECQ disorder: Bloom syn-
drome, a rare autosomal recessive condition, which presents
with mental retardation, immunodeficiency, male infertility,
and increased chance of cancer. Similar features occur in
some patients with AE, in the form of immunodeficiency,
mental retardation, and infertility. In addition, Mann et al.
[10] identified distinctive skin abnormalities in a mutant
RECQL4 mouse model. Although the GPAA1 gene is known
to be expressed in skin (Table 3), no disorder has been
identified to date that has been directly affected by GPAA1
genetic mutation, although rare cases have been reported
in which GPAA1 gene amplification and RNA and protein
overexpression occurred in hepatocellular carcinoma [11].
Further research is required to explore a putative link between
GPAA1 and RECQL4 mutations and AE.
Our data supports pathogenicity of the p.Gly512Trp
change in SLC39A4, but in additionwe have identified poten-
tially deleterious variants in SLC39A4 interacting partners
which may be important to disease pathogenesis and are
potential therapeutic targets.
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